MESOBLAST FILES Q4 2023 QUARTERLY REPORT (APPENDIX 4C)
Ticker: MEOBF · Form: 6-K · Filed: Feb 1, 2024 · CIK: 1345099
| Field | Detail |
|---|---|
| Company | Mesoblast LTD (MEOBF) |
| Form Type | 6-K |
| Filed Date | Feb 1, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: quarterly-report, compliance, foreign-issuer
TL;DR
**Mesoblast just dropped its Q4 2023 quarterly report, a standard update.**
AI Summary
Mesoblast Limited, a global leader in cellular medicines, filed its quarterly report (Appendix 4C) for the quarter ended December 31, 2023, with the Australian Securities Exchange on January 31, 2024. This filing, signed by Company Secretary Paul Hughes, indicates the company's ongoing compliance with reporting requirements for foreign private issuers. For investors, this matters because it provides a routine update on the company's financial activities and operational status, which can influence stock performance.
Why It Matters
This filing provides a routine financial update for Mesoblast, offering transparency into its operations for the quarter ended December 31, 2023, which can inform investor decisions.
Risk Assessment
Risk Level: low — This is a routine compliance filing and does not inherently introduce new risks or significant changes.
Analyst Insight
Investors should review the full Appendix 4C report (Exhibit 99.1) for detailed financial and operational performance for Q4 2023, as this 6-K only serves as a cover for that document.
Key Players & Entities
- Mesoblast Limited (company) — the registrant filing the 6-K
- Paul Hughes (person) — Company Secretary who signed the report
- Silviu Itescu (person) — Chief Executive Officer and Executive Director of Mesoblast Limited
- Australian Securities Exchange (company) — where Mesoblast filed its quarterly report
Forward-Looking Statements
- Mesoblast will continue to file routine compliance reports as a foreign private issuer. (Mesoblast Limited) — high confidence, target: Ongoing
FAQ
What is the purpose of Mesoblast Limited's 6-K filing dated January 31, 2024?
The purpose of Mesoblast Limited's 6-K filing is to report as a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, specifically to attach and incorporate by reference their quarterly report (Appendix 4C) for the quarter ended December 31, 2023, filed with the Australian Securities Exchange.
Who signed the 6-K report on behalf of Mesoblast Limited?
The 6-K report was signed by Paul Hughes, identified as the Company Secretary of Mesoblast Limited, on January 31, 2024.
What period does the attached Appendix 4C cover?
The attached Appendix 4C, which is Exhibit 99.1, is a quarterly report for the quarter ended December 31, 2023.
Where are Mesoblast Limited's principal executive offices located?
Mesoblast Limited's principal executive offices are located at Level 38, 55 Collins Street, Melbourne 3000, Australia.
What is Mesoblast Limited's Commission File Number with the SEC?
Mesoblast Limited's Commission File Number with the SEC is 001-37626.
Filing Stats: 228 words · 1 min read · ~1 pages · Grade level 18.1 · Accepted 2024-01-31 21:34:30
Filing Documents
- a2024-02x01appendix4c.htm (6-K) — 20KB
- exhibit991.htm (EX-99.1) — 32KB
- exhibit991001.jpg (GRAPHIC) — 263KB
- exhibit991002.jpg (GRAPHIC) — 260KB
- exhibit991003.jpg (GRAPHIC) — 275KB
- exhibit991004.jpg (GRAPHIC) — 249KB
- exhibit991005.jpg (GRAPHIC) — 118KB
- exhibit991006.jpg (GRAPHIC) — 123KB
- exhibit991007.jpg (GRAPHIC) — 100KB
- exhibit991008.jpg (GRAPHIC) — 108KB
- exhibit991009.jpg (GRAPHIC) — 208KB
- exhibit991010.jpg (GRAPHIC) — 159KB
- exhibit991011.jpg (GRAPHIC) — 116KB
- 0001345099-24-000015.txt ( ) — 2781KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated January 31, 2024 INDEX TO EXHIBITS Item 99.1 Appendix 4C of Mesoblast Ltd, dated January 31, 2024.